Imatinib Actavis

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
05-07-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
05-07-2022
Public Assessment Report Public Assessment Report (PAR)
05-07-2022

Active ingredient:

imatinib

Available from:

Actavis Group PTC ehf

ATC code:

L01EA01

INN (International Name):

imatinib

Therapeutic group:

Protein kinase inhibitors, Antineoplastic agents

Therapeutic area:

Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Myelodysplastic-Myeloproliferative Diseases; Hypereosinophilic Syndrome; Dermatofibrosarcoma

Therapeutic indications:

Imatinib Actavis is indicated for the treatment of: , paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with Ph+ CML in blast crisis;, adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery. , The effect of imatinib on the outcome of bone marrow transplantation has not been determined. Imatinib Actavis is indicated for: , In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic DFSP. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited. There are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.

Product summary:

Revision: 13

Authorization status:

Withdrawn

Authorization date:

2013-04-17

Patient Information leaflet

                                75
B. PACKAGE LEAFLET
Medicinal product no longer authorised
76
PACKAGE LEAFLET: INFORMATION FOR THE USER
IMATINIB ACTAVIS 50 MG HARD CAPSULES
imatinib
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE
BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Imatinib Actavis is and what it is used for
2.
What you need to know before you take Imatinib Actavis
3.
How to take Imatinib Actavis
4.
Possible side effects
5.
How to store Imatinib Actavis
6.
Contents of the pack and other information
1.
WHAT IMATINIB ACTAVIS IS AND WHAT IT IS USED FOR
Imatinib Actavis is a medicine containing an active substance called
imatinib. This medicine works by
inhibiting the growth of abnormal cells in the diseases listed below.
These include some types of
cancer.
IMATINIB ACTAVIS IS A TREATMENT FOR:
-
CHRONIC MYELOID LEUKAEMIA (CML).
Leukaemia is a cancer of white blood cells. These white
cells usually help the body to fight infection. Chronic myeloid
leukaemia is a form of leukaemia
in which certain abnormal white cells (named myeloid cells) start
growing out of control.
In adult patients, Imatinib Actavis is intended for use in the most
advanced phase of the disease (blast
crisis). In children and adolescents, Imatinib Actavis can be used in
different phases of the disease
(chronic, accelerated phase and blast crisis).
-
PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA
(PH-POSITIVE ALL)
.
Leukaemia is a cancer of white blood cells. These white cells usually
help the body to fight
infection. Acute lymphoblastic leukaemia is a form of leukaem
                                
                                Read the complete document

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Imatinib Actavis 50 mg hard capsules
Imatinib Actavis 100 mg hard capsules
Imatinib Actavis 400 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Imatinib Actavis 50 mg hard capsules
Each hard capsule contains 50 mg imatinib (as mesilate).
Imatinib Actavis 100 mg hard capsules
Each hard capsule contains 100 mg imatinib (as mesilate).
Imatinib Actavis 400 mg hard capsules
Each hard capsule contains 400 mg imatinib (as mesilate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule (capsule).
Imatinib Actavis 50 mg hard capsules
Hard capsule of size 3 with light yellow cap and light yellow body
imprinted with “50 mg” in black
ink.
Imatinib Actavis 100 mg hard capsules
Hard capsule of size 1 with light orange cap and light orange body
imprinted with “100 mg” in black
ink.
Imatinib Actavis 400 mg hard capsules
Hard capsule of size 00 with orange opaque colour cap and body
imprinted with “400 mg” in black
ink.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Imatinib Actavis is indicated for the treatment of
-
paediatric patients with newly diagnosed Philadelphia chromosome
(bcr-abl) positive (Ph+)
chronic myeloid leukaemia (CML) for whom bone marrow transplantation
is not considered as
the first line of treatment.
-
paediatric patients with Ph+ CML in chronic phase after failure of
interferon-alpha therapy, or
in accelerated phase or blast crisis.
-
adult patients with Ph+ CML in blast crisis.
-
adult and paediatric patients with newly diagnosed Philadelphia
chromosome positive acute
lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.
-
adult patients with relapsed or refractory Ph+ ALL as monotherapy.
-
adult patients with myelodysplastic/myeloproliferative diseases
(MDS/MPD) associated with
platelet-derived growth factor receptor (PDGFR) gene re-arrangements.
-
adult patients with advanced hypereosinophilic syndrome (HES) and/or
                                
                                Read the complete document

Similar products

Active ingredient imatinib

imatinib

ATC code L01EA01

L01EA01

Marketed by Actavis Group PTC ehf

Actavis Group PTC ehf

INN (International Name) imatinib

imatinib

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-07-2022
Public Assessment Report Public Assessment Report Bulgarian 05-07-2022
Patient Information leaflet Patient Information leaflet Spanish 05-07-2022
Summary of Product characteristics Summary of Product characteristics Spanish 05-07-2022
Public Assessment Report Public Assessment Report Spanish 05-07-2022
Patient Information leaflet Patient Information leaflet Czech 05-07-2022
Summary of Product characteristics Summary of Product characteristics Czech 05-07-2022
Public Assessment Report Public Assessment Report Czech 05-07-2022
Patient Information leaflet Patient Information leaflet Danish 05-07-2022
Summary of Product characteristics Summary of Product characteristics Danish 05-07-2022
Public Assessment Report Public Assessment Report Danish 05-07-2022
Patient Information leaflet Patient Information leaflet German 05-07-2022
Summary of Product characteristics Summary of Product characteristics German 05-07-2022
Public Assessment Report Public Assessment Report German 05-07-2022
Patient Information leaflet Patient Information leaflet Estonian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Estonian 05-07-2022
Public Assessment Report Public Assessment Report Estonian 05-07-2022
Patient Information leaflet Patient Information leaflet Greek 05-07-2022
Summary of Product characteristics Summary of Product characteristics Greek 05-07-2022
Public Assessment Report Public Assessment Report Greek 05-07-2022
Patient Information leaflet Patient Information leaflet French 05-07-2022
Summary of Product characteristics Summary of Product characteristics French 05-07-2022
Public Assessment Report Public Assessment Report French 05-07-2022
Patient Information leaflet Patient Information leaflet Italian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Italian 05-07-2022
Public Assessment Report Public Assessment Report Italian 05-07-2022
Patient Information leaflet Patient Information leaflet Latvian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Latvian 05-07-2022
Public Assessment Report Public Assessment Report Latvian 05-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-07-2022
Public Assessment Report Public Assessment Report Lithuanian 05-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 05-07-2022
Public Assessment Report Public Assessment Report Hungarian 05-07-2022
Patient Information leaflet Patient Information leaflet Maltese 05-07-2022
Summary of Product characteristics Summary of Product characteristics Maltese 05-07-2022
Public Assessment Report Public Assessment Report Maltese 05-07-2022
Patient Information leaflet Patient Information leaflet Dutch 05-07-2022
Summary of Product characteristics Summary of Product characteristics Dutch 05-07-2022
Public Assessment Report Public Assessment Report Dutch 05-07-2022
Patient Information leaflet Patient Information leaflet Polish 05-07-2022
Summary of Product characteristics Summary of Product characteristics Polish 05-07-2022
Public Assessment Report Public Assessment Report Polish 05-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 05-07-2022
Public Assessment Report Public Assessment Report Portuguese 05-07-2022
Patient Information leaflet Patient Information leaflet Romanian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Romanian 05-07-2022
Public Assessment Report Public Assessment Report Romanian 05-07-2022
Patient Information leaflet Patient Information leaflet Slovak 05-07-2022
Summary of Product characteristics Summary of Product characteristics Slovak 05-07-2022
Public Assessment Report Public Assessment Report Slovak 05-07-2022
Patient Information leaflet Patient Information leaflet Slovenian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 05-07-2022
Public Assessment Report Public Assessment Report Slovenian 05-07-2022
Patient Information leaflet Patient Information leaflet Finnish 05-07-2022
Summary of Product characteristics Summary of Product characteristics Finnish 05-07-2022
Public Assessment Report Public Assessment Report Finnish 05-07-2022
Patient Information leaflet Patient Information leaflet Swedish 05-07-2022
Summary of Product characteristics Summary of Product characteristics Swedish 05-07-2022
Public Assessment Report Public Assessment Report Swedish 05-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 05-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 05-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 05-07-2022
Patient Information leaflet Patient Information leaflet Croatian 05-07-2022
Summary of Product characteristics Summary of Product characteristics Croatian 05-07-2022
Public Assessment Report Public Assessment Report Croatian 05-07-2022

Search alerts related to this product

Alerts Imatinib Actavis

Imatinib Actavis

View documents history

Documents history Documents history

Imatinib Actavis